*Disseminated on Behalf of VolitionRx Ltd. Please see disclosures below. |
| Put VolitionRX On Your Radar |
| | | Hey Folks, In the world of medical diagnostics, there is a constant push to find diseases earlier, when they are more treatable.
One small company that has been quietly building technology in this space is VolitionRX (VNRX). While still a development-stage company with significant risks, its approach to blood-based testing has attracted partnerships with some notable names in diagnostics.
What Does the Company Actually Do?
At its core, Volition develops blood tests based on something called nucleosomes. The company's technology measures these nucleosomes and looks for specific patterns that can indicate disease.
The company has built what it calls its Nu.Q platform around this science. Rather than requiring expensive equipment or specialized laboratories, Volition has designed its tests to work across different settings, from large reference labs to point-of-care devices that could be used in a doctor's office. | | | Key Product Lines Under Development
Volition has organized its efforts into four main areas, each targeting different markets and applications.
1. Veterinary Testing represents the company's most commercially advanced product. The Nu.Q Vet Cancer Test helps veterinarians screen dogs for cancer through a simple blood draw. Cancer is the leading cause of death in dogs over age two, and early detection can significantly improve outcomes. The test is already available in the United States, Europe, Australia, and parts of Asia through distributors including Antech and IDEXX. According to company materials, they sold over 120,000 tests and components in 2024.
2. Human Cancer Applications are still in clinical validation stages. The company is working with hospitals in Europe and Asia to study how its technology might help with early detection, monitoring treatment response, and detecting minimal residual disease (the small number of cancer cells that can remain after treatment and potentially cause relapse).
3. Sepsis and Inflammatory Conditions represent another major focus. Sepsis is the number one cause of death in hospitals worldwide, claiming an estimated 11 million lives annually. Current diagnostic methods are slow and imprecise. Volition's Nu.Q NETs test measures neutrophil extracellular traps, which are part of the immune response and are associated with poor outcomes in sepsis patients. This product has received CE marking for use in Europe.
4. Research Services through Nu.Q Discover allows pharmaceutical companies and scientists to use Volition's technology in drug development and clinical studies. | | | The Business Model: Licensing Rather Than Building
One aspect that differentiates Volition from many diagnostics companies is its asset-light approach. Rather than building its own laboratories, manufacturing facilities, and sales teams, the company focuses on developing technology and intellectual property, then licensing it to larger partners who handle commercialization.
This strategy has produced some notable partnerships:
✓ Antech, a major veterinary diagnostics company, has an exclusive licensing agreement that has generated $10 million upfront and $13 million in milestone payments to date ✓ Fujifilm is working on automated testing platforms for the veterinary cancer test ✓ Werfen recently signed a research license for the NETs technology focused on a condition called Antiphospholipid Syndrome ✓ Hologic Diagenode entered a co-marketing agreement for research applications
The company states it is currently in confidential licensing discussions with 11 large diagnostic and liquid biopsy companies worldwide.
Intellectual Property Position
For a technology-focused company pursuing a licensing model, intellectual property protection is critical.
According to its corporate materials, Volition has 71 patents granted with coverage extending to 2044, organized across 56 patent families. This extensive IP portfolio could provide competitive advantages if the technology proves clinically useful. | | | Market Opportunity and Growth Projections
The company points to substantial market opportunities across its product lines:
✓ Veterinary cancer testing: over $1 billion total addressable market ✓ Human cancer screening: $4 billion addressable market ✓ NETs and sepsis applications: $3 billion in ICU and emergency department settings ✓ Research use: $200 million market
For its lung cancer applications specifically, the company projects Nu.Q for screening and disease management could reach over 3 million tests by 2035!
Near-Term Catalysts to Watch
Several developments could affect the company's trajectory over the coming quarters:
✓ A $5 million milestone payment tied to use in feline cancer testing ✓ Potential licensing deals for cancer and NETs technology ✓ Results from ongoing clinical studies at research centers in Europe and the United States ✓ Possible adoption into Taiwan's national lung cancer screening program, potentially beginning in the first half of 2026 |  | Worth a Closer Look?
VolitionRX represents an interesting case study in applying state-of-the-art science to practical diagnostic applications.
Its licensing-focused business model and growing patent portfolio differentiate it from companies trying to build their own testing infrastructure. The veterinary product provides some commercial validation, while human health applications remain largely in development.
For those interested in the diagnostics sector, Volition may be worth monitoring as clinical data matures and licensing discussions progress.
Anyways...
That's all for now!
Until Next Time,
-ZT Team | P.S. Want our text alerts? Text "ZIPTRADER" to 1-(855)-228-1598 to sign up!
(standard carrier data/text rates apply) |
|
|
|---|
|
*Disseminated on Behalf of VolitionRx Ltd. Please see disclosures below. |
|
|---|
|
| | 5101 SANTA MONICA BLVD STE 8 #62, 90029, LOS ANGELES, CA |
| This email was sent to ignoble.experiment@arconati.us |
| *SPONSORED CONTENT* ZipTrader LLC is a publishing company, we are not financial advisors. This is not financial advice. Investments involve risk and are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance. ZipTrader has been compensated thirty-four thousand USD by ACH Bank Transfer by TD Media LLC to distribute media via YouTube, email, and SMS on behalf of VolitionRx Ltd (VNRX) from February 24, 2026 to February 25, 2026. ZipTrader has been compensated fifteen thousand USD by ACH Bank Transfer by TD Media LLC to distribute media via email and SMS on behalf of VolitionRx Ltd (VNRX) from January 19, 2026 to January 20, 2026. ZipTrader has been compensated thirty-four thousand USD by ACH Bank Transfer by TD Media LLC to distribute media via YouTube, email, and SMS on behalf of VolitionRx Ltd (VNRX) from December 16, 2025 to December 17, 2025. ZipTrader may receive additional campaigns in the future by TD Media LLC to distribute media for VolitionRx Ltd (VNRX). As a result of this advertisement and other marketing efforts, ZipTrader may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of ZipTrader do not hold a position in VolitionRx Ltd (VNRX). This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of VolitionRx Ltd (VNRX), increased trading volume, and possibly an increased share price of VolitionRx Ltd (VNRX), which may or may not be temporary and decrease once the marketing arrangement has ended. |
| BY READING THIS EMAIL & ALL ZIPTRADER CONTENT YOU AGREE: This is not financial advice. You must do your own due diligence on all information. ZIPTRADER LLC is a publishing company and we provide general information, opinions, & news coverage to viewers. However – we do not provide personalized financial advice, are not financial advisors, and our opinions are not suitable for all investors. You should not treat any opinion as expressed as a specific inducement to make a particular investment or follow a particular strategy, but just as an opinion. Use at your own risk. Past Performance is not indicative of future results, and any results presented are not typical, and should not be understood as typical. Actual results vary given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. TRADING IS RISKY: Most traders in all markets lose all of their money (and more if they use margin). Most small businesses fail. Do NOT partake in trading, investing, entrepreneurship or any other risky endeavor covered here if you are not prepared with the reality that most fail. We reserve the right to have affiliate relationships with advertisers/sponsors. See Full Terms of Service. See Our Advertisement Disclaimer. |
| | |
|
|
|---|
|
|
|
No comments:
Post a Comment
Keep a civil tongue.